儿童癌症幸存者良性脑膜瘤风险:DCOG-LATER队列中放疗剂量、受照颅内容积与年龄的作用
荷兰DCOG-LATER队列纳入5843例儿童癌症5年幸存者,中位随访23.3年,97例发生良性脑膜瘤。与颅脑放疗剂量1-19 Gy相比,未放疗者脑膜瘤风险低(HR=0.04),20-39 Gy者HR=1.66,40+ Gy者HR=2.81;诊断年龄小于5岁较10-17岁风险增高(HR=2.38)。任何颅脑放疗后40年累积发病率为12.4%。
要点
- 与颅脑放疗剂量1-19 Gy相比,未放疗者脑膜瘤风险低(HR=0.04,95%CI 0.01-0.15)。
- 与颅脑放疗剂量1-19 Gy相比,40+ Gy者脑膜瘤风险增高(HR=2.81,95%CI 1.30-6.08)。
- 癌症诊断年龄小于5岁较10-17岁脑膜瘤风险增高(HR=2.38,95%CI 1.39-4.07)。
核心结论
- 颅脑放疗后至40岁时约八分之一幸存者发生晚期脑膜瘤,风险与放疗剂量和受照时年龄相关,对未来治疗方案及幸存者和医生的警觉有参考意义。
研究设计与样本
- 荷兰儿童肿瘤长期效应(DCOG-LATER)队列纳入1963-2001年诊断的儿童癌症5年幸存者5843例,中位随访23.3年(范围5.0-52.2年)。
- 组织学确诊的良性脑膜瘤从基于人群的荷兰病理登记库(PALGA;1990-2015年)识别,采用多变量Cox回归和线性超额相对危险(ERR)模型分析。
主要发现
- 5843例幸存者中97例发生良性脑膜瘤,其中80例发生于全容积颅脑放疗后、14例发生于部分容积颅脑放疗后。
- 与颅脑放疗剂量1-19 Gy相比,未放疗者脑膜瘤风险低(HR=0.04,95%CI 0.01-0.15),20-39 Gy者风险增高(HR=1.66,95%CI 0.83-3.33),40+ Gy者风险增高(HR=2.81,95%CI 1.30-6.08)。
- 癌症诊断年龄小于5岁较10-17岁脑膜瘤风险显著增高(HR=2.38,95%CI 1.39-4.07)。
- 剂量校正模型中,全容积与部分容积颅脑放疗相比风险无显著增高(HR=1.66,95%CI 0.86-3.22)。
- 总体ERR/Gy为0.30(95%CI 0.03-未知),剂量效应未随受照年龄或颅脑放疗容积显著变化;任何颅脑放疗后40年累积发病率为12.4%(95%CI 9.8%-15.2%)。
局限性
- 卡铂与脑膜瘤风险的关联未见剂量反应,且所有9例暴露病例均接受高剂量颅脑放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pediatric cranial radiotherapy (CrRT) markedly increases risk of meningiomas. We studied meningioma risk factors with emphasis on independent and joint effects of CrRT dose, exposed cranial volume, exposure age, and chemotherapy. METHODS: The Dutch Cancer Oncology Group-Long-Term Effects after Childhood Cancer (DCOG-LATER) cohort includes 5-year childhood cancer survivors (CCSs) whose cancers were diagnosed in 1963-2001. Histologically confirmed benign meningiomas were identified from the population-based Dutch Pathology Registry (PALGA; 1990-2015). We calculated cumulative meningioma incidence and used multivariable Cox regression and linear excess relative risk (ERR) modeling. RESULTS: Among 5843 CCSs (median follow-up: 23.3 y, range: 5.0-52.2 y), 97 developed a benign meningioma, including 80 after full- and 14 after partial-volume CrRT. Compared with CrRT doses of 1-19 Gy, no CrRT was associated with a low meningioma risk (hazard ratio [HR] = 0.04, 95% CI: 0.01-0.15), while increased risks were observed for CrRT doses of 20-39 Gy (HR = 1.66, 95% CI: 0.83-3.33) and 40+ Gy (HR = 2.81, 95% CI: 1.30-6.08). CCSs whose cancers were diagnosed before age 5 versus 10-17 years showed significantly increased risks (HR = 2.38, 95% CI: 1.39-4.07). In this dose-adjusted model, volume was not significantly associated with increased risk (HR full vs partial = 1.66, 95% CI: 0.86-3.22). Overall, the ERR/Gy was 0.30 (95% CI: 0.03-unknown). Dose effects did not vary significantly according to exposure age or CrRT volume. Cumulative incidence after any CrRT was 12.4% (95% CI: 9.8%-15.2%) 40 years after primary cancer diagnosis. Among chemotherapy agents (including methotrexate and cisplatin), only carboplatin (HR = 3.55, 95% CI: 1.62-7.78) appeared associated with meningioma risk. However, we saw no carboplatin dose-response and all 9 exposed cases had high-dose CrRT. CONCLUSION: After CrRT 1 in 8 survivors developed late meningioma by age 40 years, associated with radiation dose and exposure age, relevant for future treatment protocols and awareness among survivors and physicians.
引用
- Kok JL, Teepen JC, van Leeuwen FE, et al. Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. Neuro Oncol. 2019. PMID: 30099534. doi:10.1093/neuonc/noy124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。